Compare LCTX & BGIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCTX | BGIN |
|---|---|---|
| Founded | 1990 | 2019 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.7M | 343.9M |
| IPO Year | N/A | 2025 |
| Metric | LCTX | BGIN |
|---|---|---|
| Price | $1.65 | $2.55 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $4.25 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 39.7K |
| Earning Date | 11-06-2025 | 01-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $10,816,000.00 | ★ $205,457,324.00 |
| Revenue This Year | $6.32 | N/A |
| Revenue Next Year | $124.49 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 24.05 | N/A |
| 52 Week Low | $0.37 | $2.47 |
| 52 Week High | $2.09 | $6.50 |
| Indicator | LCTX | BGIN |
|---|---|---|
| Relative Strength Index (RSI) | 43.84 | N/A |
| Support Level | $1.63 | N/A |
| Resistance Level | $1.77 | N/A |
| Average True Range (ATR) | 0.08 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 16.67 | 0.00 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
BGIN Blockchain Ltd is operating through its subsidiaries and is engaged in digital asset technology company based in Singapore, Hong Kong and the U.S. with proprietary cryptocurrency-mining technologies and a strategic focus on alternative cryptocurrencies. It design and sell mining machines equipped with proprietary 8nm or 12nm ASIC chips under different series dedicated to the mining of KAS coins, ALPH coins, and RXD coins. The Company operated in two reportable segments, which were the cryptocurrency mining and the sale of mining machines Key revenue is generated from Sale of mining machines. Geographically, It derives key revenue from Hong Kong, China and Vietnam, United States, Singapore, etc.